他汀类药物在临床治疗中的应用综述

Lipid insights Pub Date : 2016-11-14 DOI:10.4137/LPI.S37450
Jonathan T. Davies, Spencer Delfino, Chad E. Feinberg, Meghan Johnson, Veronica L. Nappi, Joshua T. Olinger, Anthony P. Schwab, H. Swanson
{"title":"他汀类药物在临床治疗中的应用综述","authors":"Jonathan T. Davies, Spencer Delfino, Chad E. Feinberg, Meghan Johnson, Veronica L. Nappi, Joshua T. Olinger, Anthony P. Schwab, H. Swanson","doi":"10.4137/LPI.S37450","DOIUrl":null,"url":null,"abstract":"Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular disease. Statin use may expand considerably given its potential for treating an array of cholesterol-independent diseases. However, the lack of conclusive evidence supporting these emerging therapeutic uses of statins brings to the fore a number of unanswered questions including uncertainties regarding patient-to-patient variability in response to statins, the most appropriate statin to be used for the desired effect, and the efficacy of statins in treating cholesterol-independent diseases. In this review, the adverse effects, costs, and drug–drug and drug–food interactions associated with statin use are presented. Furthermore, we discuss the pleiotropic effects associated with statins with regard to the onset and progression of autoimmune and inflammatory diseases, cancer, neurodegenerative disorders, strokes, bacterial infections, and human immunodeficiency virus. Understanding these issues will improve the prognosis of patients who are administered statins and potentially expand our ability to treat a wide variety of diseases.","PeriodicalId":18039,"journal":{"name":"Lipid insights","volume":"18 1","pages":"13 - 29"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"122","resultStr":"{\"title\":\"Current and Emerging Uses of Statins in Clinical Therapeutics: A Review\",\"authors\":\"Jonathan T. Davies, Spencer Delfino, Chad E. Feinberg, Meghan Johnson, Veronica L. Nappi, Joshua T. Olinger, Anthony P. Schwab, H. Swanson\",\"doi\":\"10.4137/LPI.S37450\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular disease. Statin use may expand considerably given its potential for treating an array of cholesterol-independent diseases. However, the lack of conclusive evidence supporting these emerging therapeutic uses of statins brings to the fore a number of unanswered questions including uncertainties regarding patient-to-patient variability in response to statins, the most appropriate statin to be used for the desired effect, and the efficacy of statins in treating cholesterol-independent diseases. In this review, the adverse effects, costs, and drug–drug and drug–food interactions associated with statin use are presented. Furthermore, we discuss the pleiotropic effects associated with statins with regard to the onset and progression of autoimmune and inflammatory diseases, cancer, neurodegenerative disorders, strokes, bacterial infections, and human immunodeficiency virus. Understanding these issues will improve the prognosis of patients who are administered statins and potentially expand our ability to treat a wide variety of diseases.\",\"PeriodicalId\":18039,\"journal\":{\"name\":\"Lipid insights\",\"volume\":\"18 1\",\"pages\":\"13 - 29\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"122\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lipid insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/LPI.S37450\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lipid insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/LPI.S37450","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 122

摘要

他汀类药物是一类抑制3-羟基-3-甲基-戊二酰辅酶a还原酶的降胆固醇药物,通常用于治疗动脉粥样硬化性心血管疾病。考虑到他汀类药物治疗一系列非胆固醇依赖型疾病的潜力,其应用可能会大幅扩大。然而,由于缺乏确凿的证据支持他汀类药物的这些新兴治疗用途,许多未解决的问题浮出了我们的面前,包括他汀类药物在患者对他汀类药物的反应差异、最合适的他汀类药物用于预期效果以及他汀类药物治疗胆固醇非依赖型疾病的有效性等方面的不确定性。在这篇综述中,介绍了与他汀类药物使用相关的不良反应、成本以及药物-药物和药物-食品相互作用。此外,我们还讨论了他汀类药物在自身免疫和炎症性疾病、癌症、神经退行性疾病、中风、细菌感染和人类免疫缺陷病毒的发病和进展方面的多效性作用。了解这些问题将改善服用他汀类药物的患者的预后,并有可能扩大我们治疗各种疾病的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Current and Emerging Uses of Statins in Clinical Therapeutics: A Review
Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular disease. Statin use may expand considerably given its potential for treating an array of cholesterol-independent diseases. However, the lack of conclusive evidence supporting these emerging therapeutic uses of statins brings to the fore a number of unanswered questions including uncertainties regarding patient-to-patient variability in response to statins, the most appropriate statin to be used for the desired effect, and the efficacy of statins in treating cholesterol-independent diseases. In this review, the adverse effects, costs, and drug–drug and drug–food interactions associated with statin use are presented. Furthermore, we discuss the pleiotropic effects associated with statins with regard to the onset and progression of autoimmune and inflammatory diseases, cancer, neurodegenerative disorders, strokes, bacterial infections, and human immunodeficiency virus. Understanding these issues will improve the prognosis of patients who are administered statins and potentially expand our ability to treat a wide variety of diseases.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effects of Phenylalanine on the Liquid-Expanded and Liquid-Condensed States of Phosphatidylcholine Monolayers. Cholesterol-Binding Sites in GIRK Channels: The Devil is in the Details. Some Lipid Droplets Are More Equal Than Others: Different Metabolic Lipid Droplet Pools in Hepatic Stellate Cells. Intracellular Lipid Droplets: From Structure to Function. Four Acyltransferases Uniquely Contribute to Phospholipid Heterogeneity in Saccharomyces cerevisiae
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1